Alexandra Kurtesi

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity.

Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: April 17, 2025

Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice.

Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice.

Journal: PloS one

Published: May 03, 2024

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.

Journal: NPJ vaccines

Published: April 04, 2024

Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity.

Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity.

Journal: Mucosal immunology

Published: November 07, 2023

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.

Journal: The Lancet. Infectious diseases

Published: May 15, 2023

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.

Journal: Nature communications

Published: April 27, 2023

BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.

BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 26, 2023

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab.

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab.

Journal: The Lancet. Infectious diseases

Published: February 18, 2023

Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study.

Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 05, 2023

Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients.

Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: August 31, 2022

Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings.

Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings.

Journal: Nature communications

Published: April 21, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026